Professor Gus Gazzard (A, 1982 – 87) reflects on his journey from receiving an Industrial Scholarship at Winchester College, to becoming a pioneering researcher and Ophthalmologist where the foundations of original thinking from Winchester College guide the approach to his work every day.
Read the interview with Professor Gazzard in the Wykeham Journal here
Glaucoma: Thinking Outside the OR
An article by Professor Gazzard on this subject has recently been published in The Ophthalmologist
The full article can be viewed here.
Professor Gazzard has been ranked as one of the Top 100 Ophthalmologists in the world since 2020, most recently in 2025.
Talking Optics podcast: The changing face of glaucoma management
Optician content editor Andrew McCarthy-McClean talks to Professor Gus Gazzard about how glaucoma treatment and management is evolving.
“Performing MIGS at the time of cataract surgery offers several advantages”
Leading international Glaucoma Surgeon Gus Gazzard shares his insight into the importance of performing routine Phaco+MIGS as part of a five-part supplement in CRST Global.
Professor Gazzard is offsetting all carbon from conference travel so that Private Practice and Academic work is all ‘Carbon Neutral’ for travel, with offsets, from this year. This is in line with UCL policy of zero landfill and carbon neutrality.
The Impact of Baseline Intraocular Pressure on Initial Treatment Response in the LiGHT Trial
Article published by Professor Gus Gazzard and co-authors in American Academy of Ophthalmology.
The article is describing the advantages of Selective Laser Trabeculoplasty versus Medication in the treatment of Glaucoma.
More Evidence to Support Shift in Standard Glaucoma Care
Six-year study results show laser treatment can preserve vision better than daily eye drops.
The trial run by chief investigator Prof Gus Gazzard, compared selective laser trabeculoplasty and glaucoma eye drops as first-line treatment in patients recently diagnosed with open-angle glaucoma or ocular hypertension.
Read the full article by the American Academy of Ophthalmology here
Evolving towards an interventional glaucoma mindset
By Gus Gazzard and Jan Beiting
Traditionally, a newly diagnosed glaucoma patient would be treated first with medical therapy. As the disease progressed or the initial intervention failed to adequately control intraocular pressure (IOP), clinicians would add more drops, selective laser trabeculoplasty (SLT), repeated SLT and still more drops, with surgery as a last resort.
In this article, Gus Gazzard and Jan Beiting discuss how this paradigm has now changed thanks to SLT and a new approach to glaucoma care.
Visual Field Progression in the LiGHT Trial
Gus Gazzard, FRCOphth, MA, MBBChir, MD, analyzes the 6-year rate of visual field progression in the laser in glaucoma and ocular hypertension (LiGHT) trial comparing selective laser trabeculoplasty (SLT) and medication as first-line glaucoma treatment. He reviews information presented during glaucoma subspecialty day at the American Academy of Ophthalmology annual meeting.
Posted: 10/25/2024
SLT as First-Line Therapy
Glaucoma Today Cover Focus | January/February 2024
Exploring the foundation of the LIGHT study and the clinical applications of its outcomes.
Gus Gazzard, MBBChir, MA, MD, FRCOphth, joins Arsham Sheybani, MD, and Iqbal Ike K. Ahmed, MD, FRCSC, to discuss the background and results of the Laser in Glaucoma and Ocular HyperTension (LiGHT) study. Dr. Gazzard explains how to clinically apply its outcomes and comments on using selective laser trabeculoplasty (SLT) as potential first-line therapy.
The History of Eyecare Podcast
During the American Academy of Ophthalmology in October, Lumibird Medical USA hosted Dr. J. Morgan Micheletti, MD at their booth for a LIVE recording of The History of Eyecare. Dr. Micheletti got a chance to sit down with guests Dr. Mark Latina and Dr. Gus Gazzard.
Glaucoma: now and beyond
Impact review led by Professor Gazzard
Read more about the impact review ‘Glaucoma: now and beyond’ here
WGC Presentation
Watch BELKIN Vision’s World Glaucoma Conference Symposium in Rome – June 2023. Moderated by Dr. Paul Singh and joined in discussion by Prof. Gus Gazzard, Prof. Stefano Gandolfi and Dr. med Inga Kersten Gomez.
Professor Gazzard was voted in the World’s Top 10 Most Influential Ophthalmologists in April 2022 and again in 2023.
Read more about the Power List here
You can view Professor Gazzard’s Google Scholar page here: this compiles his research, articles and h-index.
6-Year Results Support SLT for Glaucoma & Ocular Hypertension
Article in Physician’s Weekly on the impact and importance of Gazzard’s SLT research.
Professor Gus Gazzard is number 3 on the 100 Power List for The Ophthalmologist
You can read more and the full article here
Professor Gazzard’s paper was voted the 11th most impactful Glaucoma research paper ever.
From the “The American Glaucoma Society 100 Articles with Significant Impact on Clinical Glaucoma”
You can read the full list of selected articles here (PDF download)
Article featuring Professor Gus Gazzard’s work on SLT and the LiGHT Study
“Glaucoma researchers deliver verdict on SLT versus eye drops in LiGHT study”
You can read more and the full article here
Article featuring Professor Gus Gazzard’s research “How Surgery Plus Stent Slows Glaucoma Progression Better Than Surgery Alone — Five-year follow-up shows significantly less annual visual field progression with the stent”
You can read more and the full article here
Gus’s paper was selected to be European Glaucoma Society ‘Clinical Paper of the Month’ for January 2023
Professor Gazzard was interviewed by the American Society of Cataract and Refractive Surgery on the Ophthamalogy podcast on the efficacy of repeat SLT.
(only available to ASCRS members)